### Accepted Manuscript

N-(2-methyl-indol-1H-5-yl)-1-naphthalenesulfonamide: a novel reversible antimitotic agent inhibiting cancer cell motility

Clara Aceves-Luquero, Cristina Galiana-Roselló, Guillem Ramis, Ruth Villalonga-Planells, Enrique García-España, Silvia Fernández de Mattos, Rafael Pelaez, José M. Llinares, M. Eugenia González-Rosende, Priam Villalonga

PII: DOI: Reference:	S0006-2952(16)30142-3 http://dx.doi.org/10.1016/j.bcp.2016.06.016 BCP 12576
To appear in:	Biochemical Pharmacology
Received Date:	25 April 2016
Accepted Date:	23 June 2016

Please cite this article as: C. Aceves-Luquero, C. Galiana-Roselló, G. Ramis, R. Villalonga-Planells, E. García-España, S.F.d. Mattos, R. Pelaez, J.M. Llinares, M. Eugenia González-Rosende, P. Villalonga, *N*-(2-methyl-indol-1*H*-5-yl)-1-naphthalenesulfonamide: a novel reversible antimitotic agent inhibiting cancer cell motility, *Biochemical Pharmacology* (2016), doi: http://dx.doi.org/10.1016/j.bcp.2016.06.016

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# *N*-(2-methyl-indol-1*H*-5-yl)-1-naphthalenesulfonamide: a novel reversible antimitotic agent inhibiting cancer cell motility

Clara Aceves-Luquero,<sup>1,4</sup> Cristina Galiana-Roselló,<sup>5,7</sup> Guillem Ramis,<sup>1,4</sup>Ruth Villalonga-Planells,<sup>3</sup> Enrique García-España,<sup>6</sup>Silvia Fernández de Mattos,<sup>1,2,4</sup>Rafael Pelaez,<sup>8</sup>José M. Llinares,<sup>7</sup>M. Eugenia González-Rosende<sup>5,§,\*</sup>and Priam Villalonga<sup>1,2,4,§,\*</sup>

<sup>1</sup>Cancer Cell Biology Laboratory, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS),<sup>2</sup>Departament de Biologia Fonamental i Ciències de la Salut, and<sup>3</sup>Departament de Química, Universitat de les Illes Balears, Palma, Illes Balears, Spain.<sup>4</sup>Institut d'Investigació Sanitària de Palma (IdISPa), Palma, Illes Balears, Spain. <sup>5</sup>Departamento de Farmacia, Universidad CEU-Cardenal Herrera, Moncada, Valencia, Spain.<sup>6</sup>Departamento de Química Inorgánica and <sup>7</sup>Departamento de Química Orgánica, ICMoL, Universitat de València, Paterna, Spain. <sup>8</sup>Departamento de Química Farmacéutica, Universidad de Salamanca, Salamanca, Spain.

§Joint senior co-authors.

\*Corresponding authors:

Priam Villalonga. Mailing address: Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears. EdificiCientificotècnic, Ctra. Valldemossa Km 7,5, 07122, IllesBalears, Spain. Phone: +34 971 173004 Fax: +34 971 259501 E-mail: priam.villalonga@uib.es

M. Eugenia González-Rosende. Mailing address: Departamento de Farmacia, Universidad CEU Cardenal Herrera, Avda. Seminario s/n, 46113, Moncada, Valencia, Spain. Phone: +34 961 369 000,Fax: +34961 395 272E-mail: <u>eugenia@uch.ceu.es</u>

#### Abstract

A series of compounds containing the sulfonamide scaffold were synthesized andscreened for their in vitro anticancer activity against a representative panel of human cancer cell lines, leading to the identification of N-(2-methyl-1H-indol-5-yl)-1naphthalenesulfonamide (8e) as a compound showing a remarkable activity across the panel, with IC<sub>50</sub> values in the nanomolar-to-low micromolar range. Cell cycle distribution analysis revealed that 8e promoted a severe G2/M arrest, which was followed by cellular senescence as indicated by the detection of senescenceassociated  $\beta$ -galactosidase (SA- $\beta$ -gal) in **8e**-treated cells. Prolonged **8e** treatment also led to the onset of apoptosis, in correlation with the detection of increased Caspase 3/7 activities. Despite increasingy-H2A.X levels, a well-established readout for DNA double-strand breaks, in vitro DNA binding studies with 8e did not support interaction with DNA. In agreement with this, 8e failed to activate the cellular DNA damage checkpoint. Importantly, tubulin staining showed that 8e promoted a severe disorganization of microtubules and mitotic spindle formation was not detected in 8etreated cells. Accordingly, 8e inhibited tubulin polymerization in vitro in a dosedependent manner andwas also able to robustly inhibit cancer cell motility. Docking analysis revealed a compatible interaction with the colchicine-binding site of tubulin. Remarkably, these cellular effects were reversible since disruption of treatment resulted in the reorganization of microtubules, cell cycle re-entry and loss of senescent markers. Collectively, our data suggest that this compound may be a promising new anticancer agent capable of both reducing cancer cell growth and motility.

Keywords: Sulfonamides, Cancer, Mitosis, Tubulin, Cell Motility, Apoptosis.

#### 1. Introduction

Despite overwhelming advances in cancer research and clinical oncology, which have resulted in higher successful outcomes for a number of malignancies, cancer remains the second leading cause of death in developing as well as developed countries. Moreover, the global cancer burden is growing at an alarming pace, in 2030 alone, 21.3 million new cancer cases and 13.1 million cancer deaths are expected to occur, simply due to the growth and aging of the population[1]. Even though chemotherapy is the mainstay of cancer therapy, the use of available chemotherapeutics is often limited, mainly due to undesirable side effects caused by the lack of selectivity of most antitumoral drugs as well as the constant emergence of drug-resistant and multidrug resistant tumors, which clearly underscores the need of developing alternative chemotherapeutic agents for more effective cancer treatments [2]. In this context, research efforts directed at the development of new anti-mitotic agents is clearly a priority, with the aim to addressing issues such as enhanced tumor specificity, insensitivity to chemo-resistance and reduced neurotoxicity [3]. Anti-mitotic compounds elicit their antitumor activity by altering tubulin polymerization and thus microtubule dynamics which impairs the correct assembly of the mitotic spindle, leading to mitotic arrest. Among these compounds, tubulin-inhibiting agents binding to the colchicine site on tubulin have been of special interest [4].

Sulfonamides and their derivatives constitute an important class of therapeutic agents that exhibit a broad spectrum of pharmacological profiles, such as antibacterial, diuretic, hypoglycaemic, antithyroid, antiviral, antiinflammatory and antiparasitic activities among others [5]. Particularly, compounds belonging to this structural class have also been recently reported to show substantial *in vitro* and *in vivo* anticancer activities and some of them are currently undergoing clinical trials [5d,5e,6]. Interestingly, although these novel chemotypesshare a common motif of aromatic/heterocyclic sulfonamides, a varietyof mechanisms have been involved in their antitumor action, i.e. disruption of microtubule protein assembly [6,7], carbonic anhydrase inhibition [8], cell cycle arrest [9],NF-xB transcription factorinhibition[10], Histone Deacetylase inhibition [11],Matrix Metaloproteinases (MMP) inhibition[12],as well as targeting protein kinase-mediated signaling pathways[13], or mitochondrial membrane[14].

It is also well documented that tubulin may constitute a suitable target for antiprotozoal compounds [15]. In this context, we have recently reported benzene and naphthalenesulfonamide derivatives as potent antiparasitic agents targetingβ-tubulin of Leishmaniainfantum[16]. Hence, based on our previous results on leishmanicidal tubulin-interacting sulfonamides andthe increasing biological importance of potential sulfonamides in the field of anti-tumoral chemotherapy. the antiproliferativeactivity of our in-house sulfonamide library was evaluated against a large panel of tumor cell lines. In addition, to determine electronic and structural features, we designed and synthesized a new series of sulfonamides (Figure 1). Here, we describe the identification of N-(2-methyl-1H-indol-5-yl)-1-naphthalenesulfonamide (compound 8e) as a sulfonamide with potentialanticancer activity and characterize its cellular mechanism of action as a novel, and reversible, tubulin polymerization inhibitor inducing mitotic arrest, senescence and cellular apoptosis. Importantly, we also show that sulfonamide 8e significantly inhibits cancer cell motility, enhancing the potential interest of this sulfonamide as a novel anticancer compound.

#### 2. Materials and Methods

#### 2.1. Chemistry

#### 2.1.1. General

All reagents were purchased from Aldrich and used without purification. All experiments were made under nitrogen atmosphere. Melting points were determined with a Kofler hot-stage apparatus and are uncorrected. Column chromatography was performed using silica gel (Merck 60, 70-230 mesh). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AC-300 instrument. Chemical shifts ( $\delta$  values) and coupling constants (*J* values) are given in ppm and Hz respectively. HRMS were obtained using a VG Autospec TRIO 1000 instrument. The ionization mode used in mass spectra was electron impact (EI), fast atom bombardment (FAB) or Time-of-flight mass spectroscopía Atómica, Molecular y Óptica, Universitat de València-SCSIE (Servei Central de Suport a la Investigació Experimental), València, Spain. The purity of the compounds (≥95%) and molecular mass were confirmed by elemental microanalysis and HRMS. The analytical results for C, H, and N were within ±0.4 of the theoretical values.

#### 2.1.2. Synthesis and Characterization

General procedure for the synthesis of sulfonamides 1-14. To an ice-cooled solution of the amine (20 mmol) in pyridine (8 mL) was slowly added the corresponding sulfonyl chloride (30 mmol) in pyridine (6 mL). The mixture was stirred at 0  $^{\circ}$ C for 2 h and allowed to reach room temperature. Water was added (100 mL) and the solid was collected and recrystallized from MeOH:CH<sub>2</sub>Cl<sub>2</sub>.

Compounds 1-4, 5b-d, 6a-c, and 8a-e, were synthesized as previously described [16].

*N*-(1*H*-Indazol-5-yl)-4-nitrobenzenesulfonamide (5a)[17].Yield: 73%, mp: 234-236  $^{\circ}$ C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 7.08 (d, *J* = 8.8, 1H), 7.44 (m, 2H), 7.93 (d, *J* = 8.7, 2H), 8.00 (s, 1H), 8.31 (d, *J* = 8.7, 2H), 10.5 (brs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ: 111.2 (CH), 114.1 (CH), 122.9 (CH), 123.2 (C), 124.9 (CH), 128.7 (CH), 129.6 (C), 133.9 (CH), 138.2 (C), 145.1 (C), 150.0 (C), HRMS-EI<sup>+</sup>: *m/z* calcd for C<sub>13</sub>H<sub>10</sub>N<sub>4</sub>O<sub>4</sub>S: 318.0422, found: 318.0429.

*N*-(1*H*-indol-5-yl)-1-naphthalenesulfonamide (7a). Yield 56%, mp: 107-108 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 6.29 (m, 1H), 6.76 (dd, *J* = 2, *J* = 8.6, 1H), 7.18 (d, *J* = 8.6, 1H), 7.21 (d, *J* = 2, 1H), 7.26 (t, *J* = 2.7, 1H), 7.51 (t, *J* = 7.8, 1H), 7.64 (td, *J* = 1, *J* = 8.6, 1H), 7.74 (td, *J* = 1.4, *J* = 8.6, 1H), 8.03 (d, *J* = 7.8, 1H), 8.11 (m, *2*H), 8.87 (d, *J* = 8.6, 1H), 10.22 (s, 1H, NH), 11.01 (s, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 101.4 (CH), 111.9 (CH), 113.6 (CH), 117.0 (CH), 124.7 (CH), 125.0 (CH), 126.6 (CH), 127.2 (CH), 127.9 (C), 128.1 (C), 128.2 (C), 129.0 (CH), 129.3 (CH), 130.0 (CH), 133.9 (C), 134.0 (C), 134.3 (CH), 135.2 (C), HRMS (ES<sup>+</sup>): *m/z* (M+H) calcd for C<sub>18</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub>S: 323.0849 found: 323.0826. Anal. Calcd for C<sub>18</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S: C, 67.06, H, 4.38, N, 8.69, S, 9.94. Found: C, 66.86, H, 4.65, N, 8.48, S, 9.59.

*N*-(1*H*-indol-5-yl)-5-(dimethylamino)-1-naphthalenesulfonamide (7b). Yield 74%, mp 118-121 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 2.49 (s, 6H), 6.25 (m, 1H), 6.73 (dd, J = 2.1 J = 8.6, 1H), 7.14 (d, J = 8.6, 1H), 7.15 (d, J = 2, 1H), 7.25 (m, 2H), 7.49 (t, J = 7.3, 1H), 7.61 (t, J = 8.6, 1H), 8.05 (dd, J = 1.1, J = 7.3, 1H), 8.38 (d, J = 8.6, 1H), 8.46 (d, J = 8.6, 1H), 10.13 (s, 1H, NH), 10.96 (s, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ = 45.4 (CH<sub>3</sub>), 101.3 (CH), 111.9 (CH), 113.2 (CH), 115.5 (CH), 116.7 (CH), 119.4 (CH), 123.8 (CH), 126.6 (CH), 127.9 (C), 128.2 (CH), 129.1 (C), 129.2 (C), 129.6 (C), 129.9 (CH), 130.0 (CH), 133.7 (C), 135.7 (C), 151.7 (C), HRMS (ES<sup>+</sup>): *m/z* (M+H) calcd for C<sub>20</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub>S: 366.1271 found: 366.1248. Anal. Calcd for C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S: C, 62.28, H, 4.95, N, 15.29, S, 8.75. Found: C, 62.24, H, 5.24, N, 14.71, S, 8.60.

5

*N*-(2-methyl-*1H*-indol-5-yl)-8-quinolinesulfonamide(8f). Yield 58%, mp 192-194 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 2.25 (s, 3H), 5.88 (s, 1H), 6.60 (dd, J = 2, J = 8.6, 1H), 6.94 (d, J = 8.6, 1H), 6.98 (d, J = 2, 1H), 7.58 (t, J = 7.7, 1H), 7.74 (dd, J = 4.2, J = 8.4, 1H), 8.2 (d, J = 7.7, 2H), 8.52 (dd, J = 1.7, J = 8.4, 1H), 9.21 (dd, J = 1.7, J = 4.2, 1H), 9.39 (bs, 1H, NH), 10.76 (bs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ = 13.6 (CH<sub>3</sub>), 99.3 (CH), 110.6 (CH), 113.0 (CH), 116.1 (CH), 122.9 (CH), 126.0 (CH), 128.4 (C), 128.7 (C), 129.1 (C), 132.0 (CH), 134.0 (C), 134.1 (CH), 135.8 (C), 136.9 (C), 137.4 (CH), 143.4 (C), 151.7 (CH), HRMS (ES<sup>+</sup>): m/z (M+H) calcd for C<sub>18</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub>S: 338.0958 found: 338.0934. Anal. Calcd for C<sub>18</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>S: C, 64.08, H, 4.48, N, 12.45, S, 9.50. Found: C, 63.97, H, 4.64, N, 12.01, S, 9.12.

*N*-(2-anthryl)-4-nitrobenzenesulfonamide(9a). Yield 58%, mp 183-187 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 7.05 (dd, J = 2, J = 9, 1H), 7.36 (m, 2H), 7.71 (s, 1H), 7.80 (m, 1H), 8.02 (m, 2H), 8.09 (d, J = 9, 2H), 8.35 (d, J = 9, 2H), 8.42 (s, 1H), 8.46 (s, 1H), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ = 115.6 (CH), 123.4 (CH), 125.0 (CH), 125.5 (CH), 125.6 (CH), 126.2 (CH), 126.4 (CH), 126.9 (CH), 127.4 (C), 128.0 (CH), 128.4 (CH), 130.1 (C), 132.0 (CH), 132.3 (C), 134.0 (C), 145.7 (C), 146.4 (C), 150.1 (C), HRMS (ES<sup>+</sup>): m/z (M-H) calcd for C<sub>20</sub>H<sub>13</sub>N<sub>2</sub>O<sub>4</sub>S: 377.0596, found: 377.0593. Anal. Calcd for C<sub>20</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S: C, 63.48, H, 3.73, N, 7.40, S, 8.47. Found: C, 63.95, H, 4.04, N, 7.45, S, 8.95.

*N*-(2-anthryl)-4-chlorobenzenesulfonamide (9b). Yield 53%, mp 160-161 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 7.31 (dd, *J* = 2.1, *J* = 9, 1H), 7.47 (m, 2H), 7.61 (d, *J* = 8.9, 2H), 7.70 (s, 1H), 7.84 (d, *J* = 8.9, 2H), 8.0 (m, 3H), 8.42 (s, 1H), 8.47 (s, 1H), 10.69 (bs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 115.4 (CH), 121.4 (CH), 125.5 (CH), 125.6 (CH), 126.2 (CH), 126.4 (CH), 128.0 (CH), 128.4 (CH), 128.9 (C), 129.0 (CH), 129.9 (CH), 130.1 (CH), 131.0 (C), 131.5 (C), 132.1 (C), 134.9 (C), 138.3 (C), 138.7 (C), HRMS (ES<sup>+</sup>): *m*/*z* (M+H) calcd for C<sub>20</sub>H<sub>14</sub>CINO<sub>2</sub>S: 368.0512, found: 368.0511. Anal. Calcd for C<sub>20</sub>H<sub>14</sub>CINO<sub>2</sub>S: C, 65.30, H, 3.83, N, 3.80, S, 8.71. Found: C, 63.19, H, 3.53, N, 7.45, S, 8.90.

*N*-(2-anthryl)-benzenesulfonamide(9c). Yield 97%, mp 195-197 °C (lit [18]184 °C), <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 7.31 (dd, *J* = 2.0, *J* = 9, 1H), 7.36 (m, 1H), 7.47 (m, 2H), 7.61 (d, *J* = 8.7, 2H), 7.70 (s, 1H), 7.85 (d, *J* = 8.7, 2H), 8.0 (m, 3H), 8.42 (s, 1H), 8.46 (s, 1H), 10.70 (bs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 115.4 (CH), 121.4 (CH), 125.5 (CH), 125.6 (CH), 126.2 (CH), 126.4 (CH), 128.0 (CH), 128.4 (CH), 128.9

7

(C), 129.0 (CH), 129.4 (CH), 129.8 (CH),130.1 (CH), 131.0 (C), 132.1 (C), 134.9 (C), 138.3 (C), 138.7 (C). Anal. Calcd for  $C_{20}H_{15}NO_2S$ : C, 72.05, H, 4.53, N, 4.20, S, 9.62. Found: C, 71.77, H, 4.17, N, 3.95, S, 9.44.

*N*-(2-anthryl)-1-naphthalenesulfonamide (9d).Yield 99%, mp 105-109 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 7.26 (dd, J = 2.1, J = 9, 1H), 7.43 (m, 2H), 7.64 (t, J = 8, 2H), 7.76 (m, 2H), 7.91 (d, J = 9, 1H), 7.95 (dd, J = 2.4, J = 6.8, 2H), 8.04 (d, J = 7.7, 1H), 8.19 (d, J = 8.3, 1H), 8.32 (s, 1H), 8.36 (d, J = 1.7, 1H), 8.38 (s, 1H), 8.83 (d, J = 8.5, 1H), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ = 113.5 (CH), 120.6 (CH), 124.6 (CH), 124.8 (CH), 125.1 (CH), 125.5 (CH), 126.2 (CH), 126.3 (CH), 127.4 (CH), 127.8 (C), 127.9 (CH), 128.4 (CH), 128.6 (CH), 129.5 (CH), 129.9 (CH), 130.6 (CH), 130.8 (C), 131.4 (C), 132.0 (C), 134.1 (C), 134.6 (C), 134.9 (CH), 135.0 (C), 138.8 (C). HRMS (TOF<sup>+</sup>): m/z (M+H) calcd for C<sub>24</sub>H<sub>18</sub>NO<sub>2</sub>S: 384.1053, found: 384.1047. Anal. Calcd for C<sub>24</sub>H<sub>17</sub>NO<sub>2</sub>S: C, 75.17, H, 4.47, N, 3.65, S, 8.36. Found: C, 71.77, H, 4.17, N, 3.95, S, 9.44.

*N*-(2,3-dihydro-1*H*-inden-1-yl)-1-naphthalenesulfonamide (10). Yield 46%, mp 164-165 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 1.54 (m, 1H), 1.92 (m, 1H), 2.59 (m, 1H), 2.74 (m, 1H), 4.66 (m, 1H), 6.87 (d, *J* = 7.7, 1H), 7.04 (td, *J* = 2.9, *J* = 7.7, 1H), 7.14 (m, *2*H), 7.69 (m, *3*H), 8.13 (dd, *J* = 2, *J* = 7.3, 1H), 8.25 (d, *J* = 7.3, 1H), 8.26 (d. *J* = 8.5, 1H), 8.49 (d, *J* = 9, 1H, NH), 8.73 (d, *J* = 8.5, 1H), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ = 29.7 (CH<sub>2</sub>), 33.8 (CH<sub>2</sub>), 58.2 (CH), 124.3 (CH), 124.8 (CH), 124.9 (CH), 125.3 (CH), 126.6 (CH), 127.2 (CH), 128.0 (CH), 128.1 (CH), 129.1 (CH), 129.3 (CH), 134.2 (CH), 136.8 (C), 142.2 (C), 142.8 (C), 143.0 (C), 143.4 (C), HRMS (ES<sup>+</sup>): *m/z* (M+H) calcd for  $C_{19}H_{18}NO_2S$ : 324,1053 found: 324.1037.

*N*-(2,3-dihydro-1*H*-inden-2-yl)-1-naphthalenesulfonamide(11).Yield 51%, mp 184-187 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 2.65 (dd, *J* =7.3, *J* = 15.8, 2H), 2.83 (dd, *J* =7.3, *J* = 15.8, 2H), 3.91 (sextet, *J* =7.3, 1H), 7.1 (m, 4H), 7.7 (m, 3H), 8.11 (d, *J* = 7.7, 1H), 8.21 (dd, *J* = 1.1, *J* = 7.7, 1H), 8.25 (d, *J* = 8.3, 1H), 8.38 (d, *J* = 7.5, 1H, NH), 8.70 (d, *J* = 8.3, 1H), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 37.7 (CH<sub>2</sub>), 50.18 (CH), 124.6 (CH), 125.0 (CH), 125.1 (CH), 126.8 (CH), 127.2 (CH), 127.9 (C), 128.2 (CH), 129.1 (CH), 129.3 (CH), 134.20 (CH), 134.2 (C), 136.3 (C), 140.6 (C), HRMS (ES<sup>+</sup>): *m/z* (M+H) calcd for C<sub>19</sub>H<sub>18</sub>NO<sub>2</sub>S: 324,1053 found: 324.1032. Anal. Calcd for C<sub>19</sub>H<sub>17</sub>NO<sub>2</sub>S: C, 70.56, H, 5.30, N, 4.33, S, 9.91. Found: C, 70.30, H, 5.09, N, 4.48, S, 9.59.

*N*-(2,3-dihydro-1*H*-inden-4-yl)-4-nitrobenzenesulfonamide(12a). Yield 70%, mp 175-178 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 1.82 (quintet, *J* = 7.5, 2H), 2.57 (t, *J* = 7.5, 2H), 2.77 (t, *J* = 7.5, 2H), 6.83 (dd, *J* = 3.5, *J* = 5.5, 1H), 7.03 (s, 1H), 7.05 (d, *J* = 5.5, 1H), 7.92 (d, *J* = 8.8, 2H), 8.34 (d, *J* = 8.8, 2H), 10.05 (bs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ = 24.9 (CH<sub>2</sub>), 30.6 (CH<sub>2</sub>), 33.0 (CH<sub>2</sub>), 122.7 (CH), 122.8 (CH), 124.9 (CH), 127.4 (CH), 128.5 (CH), 132.4 (C), 139.5 (C), 146.0 (C), 146.2 (C), 150.1 (C). Anal. Calcd for C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S: C, 56.59, H, 4.43, N, 8.80, S, 10.07. Found: C, 56.83, H, 4.51, N, 8.91, S, 9.68.

*N*-(2,3-dihydro-1*H*-inden-4-yl)-benzenesulfonamide(12b). Yield 96%, mp 140-143 <sup>a</sup>C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 1.77 (quintet, J = 7.5, 2H), 2.50 (t, J = 7.5, 2H), 2.75 (t, J = 7.5, 2H), 6.87 (dd, J = 2.5, J = 6.6, 1H), 7.01 (m, 2H), 7.55 (m, 3H), 7.66 (dd, J = 1.5, J = 7, 2H), 9.67 (bs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ = 24.9 (CH<sub>2</sub>), 30.4 (CH<sub>2</sub>), 33.0 (CH<sub>2</sub>), 122.2 (CH), 122.5 (CH), 126.9 (CH), 127.2 (CH), 129.5 (CH), 133.0 (CH), 133.1 (C), 139.0 (C), 140.7 (C), 145.6 (C), HRMS (TOF<sup>+</sup>): *m/z* (M+H) calcd for C<sub>15</sub>H<sub>16</sub>NO<sub>2</sub>S: 274.0896, found 274.0902. Anal. Calcd for C<sub>15</sub>H<sub>15</sub>NO<sub>2</sub>S: C, 65.91, H, 5.53, N, 5.12, S, 11.73. Found: C, 65.67, H, 5.57, N, 5.13, S, 11.72.

*N*-(2,3-dihydro-1*H*-inden-4-yl)-4-fluorobenzenesulfonamide(12c). Yield 97%, mp 115-117 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 1.80 (quintet, *J* = 7.5, 2H), 2.52 (t, *J* = 7.5, 2H), 2.77 (t, *J* = 7.5, 2H), 6.85 (dd, *J* = 2.8, *J* = 6, 1H), 7.02 (m, 2H), 7.40 (t, *J* = 8.8, 2H), 7.72 (ddd, *J* = 5.2, *J* = 8.8, 2H), 9.71 (bs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSOd<sub>6</sub>) δ = 24.9 (CH<sub>2</sub>), 30.5 (CH<sub>2</sub>), 33.0 (CH<sub>2</sub>), 116.6 (d, *J*<sub>C-F</sub> = 22.5, CH), 122.4 (CH), 122.6 (CH), 127.2 (CH), 130.0 (d, *J*<sub>C-F</sub> = 9.7, CH), 133.0 (C), 137.1 (d, *J*<sub>C-F</sub> = 3, C) 139.2 (C), 145.7 (C), 164.5 (d, *J*<sub>C-F</sub> = 247.5, C), HRMS (TOF<sup>+</sup>): *m/z* (M+H) calcd for C<sub>15</sub>H<sub>15</sub>FNO<sub>2</sub>S: 292.0802, found 292.0808.

*N*-(2,3-dihydro-1*H*-inden-4-yl)-1-naphthalenesulfonamide (12d). Yield 63%, mp 185-186 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 1.65 (q, J = 7.4, 2H), 2.39 (t, J = 7.4, 2H), 2.66 (t, J = 7.4, 2H), 6.86 (dd, J = 1.8, J = 7.3, 1H), 6.92 (d, J = 7.3, 1H), 6.96 (t, J= 7.3, 1H), 7.57 (t, J = 8.2, 1H), 7.66 (m, 2H), 8.07 (m, 2H), 8.21 (d, J = 8.2, 1H), 8.70 (m, 1H), 9.98 (bs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ = 24.7 (CH<sub>2</sub>), 30.3 (CH<sub>2</sub>), 32.9 (CH<sub>2</sub>), 121.6 (CH), 121.8 (CH), 124.8 (CH), 125.0 (CH), 127.1 (CH), 127.2 (C), 127.9 (C), 128.1 (C), 129.3 (CH), 129.6 (C), 133.0 (CH), 134.1 (C), 134.5 (C), 135.7 (CH), 138.3 (CH), 145.7 (CH), HRMS (ES<sup>+</sup>): m/z (M+H) calcd for C<sub>19</sub>H<sub>18</sub>NO<sub>2</sub>S:

324,1053 found: 324.1039. Anal. Calcd for  $C_{19}H_{17}NO_2S$ : C, 70.56, H, 5.30, N, 4.33, S, 9.91. Found: C, 70.3, H, 5.31, N, 4.46, S, 9.55.

*N*-(2,3-dihydro-1*H*-inden-5-yl)-benzenesulfonamide(13a)[17].Yield: 91%, mp: 150-154 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 1.92 (m, 2H), 2.72 (m, 4H), 6.84 (dd, *J* = 8.1, *J* = 2.1, 1H), 6.94 (s, 1H), 7.02 (d, *J* = 8.1, 1H), 7.53 (m, 3H), 7.72 (d, *J* = 7.9, 2H), 10.1 (brs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 25.4 (CH<sub>2</sub>), 31.9 (CH<sub>2</sub>), 32.6 (CH<sub>2</sub>), 117.1 (CH), 118.9 (CH), 124.9 (CH), 127.0 (CH), 129.5 (CH), 134.0 (CH), 136.0 (C), 139.9 (C), 140.0 (C), 145.4 (C), HRMS-EI<sup>+</sup>: *m/z* calcd for C<sub>15</sub>H<sub>15</sub>NO<sub>2</sub>S: 273.0823, found: 273.0826. Anal. Calcd for C<sub>15</sub>H<sub>15</sub>NO<sub>2</sub>S: C, 65.91, H, 5.53, N, 5.12, S, 11.73. Found: C, 66.075, H, 5.48, N, 5.15, S, 11.46.

*N*-(2,3-dihydro-1*H*-inden-5-yl)-4-fluorobenzenesulfonamide(13b). Yield 87%, mp 134-136 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ = 1.93 (quintet, *J* = 7, 2H), 2.73 (m, 4H), 6.82 (dd, *J* = 2, *J* = 8, 1H), 6.94 (s, 1H), 7.03 (d, *J* = 8, 1H), 7.38 (t, *J* = 8.8, 2H), 7.72 (dd, *J* = 5.1, *J* = 8.8, 2H), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>) δ = 25.4 (CH<sub>2</sub>), 32.0 (CH<sub>2</sub>), 32.6 (CH<sub>2</sub>), 116.8 (CH, d, *J*<sub>C-F</sub> = 22, CH), 117.4 (CH), 119.2 (CH), 125.0 (CH), 130.0 (d, *J*<sub>C-F</sub> = 9.75, CH), 135.8 (C), 136.3 (d, *J*<sub>C-F</sub> = 3, C), 140.3 (C), 145.1 (C), 164.5 (d, *J*<sub>C-F</sub> = 249.7, C), HRMS (ES<sup>+</sup>): *m*/*z* (M+H) calcd for C<sub>15</sub>H<sub>15</sub>FNO<sub>2</sub>S: 292.0808, found: 292.0805. Anal. Calcd for C<sub>15</sub>H<sub>14</sub>FNO<sub>2</sub>S: C, 61.84, H, 4.84, N, 4.81, S, 11.00. Found: C, 61.72, H, 4.88, N, 4.78, S, 10.95.

*N*-(2,3-dihydro-1*H*-inden-5-yl)-1-naphthalenesulfonamide(13c).Yield 88%, mp 112-115 °C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>)  $\bar{\delta}$  = 1.86 (quintet, *J* = 7.5, 2H), 2.65 (t, *J* = 7.5, 4H), 6.67 (dd, *J* = 2.1, *J* = 8, 1H), 6.88 (s, 1H), 6.94 (d, *J* = 8, 1H), 7.71 (m, 3H), 8.06 (d, *J* = 8, 1H), 8.16 (m, 2H), 8.74 (d, *J* = 8, 1H), 10.48 (bs, 1H, NH), <sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>)  $\bar{\delta}$  = 25.3 (CH<sub>2</sub>), 31.9 (CH<sub>2</sub>), 32.6 (CH<sub>2</sub>), 116.1 (CH), 117.9 (CH), 124.7 (CH),124.8 (CH), 124.9 (CH), 127.3 (CH), 127.9 (C), 128.4 (CH), 129.4 (CH), 130.1 (CH), 134.1 (C), 134.6 (CH), 135.0 (C), 136.0 (C), 139.5 (C), 144.9 (C), HRMS (ES<sup>+</sup>): *m/z* (M+Na) calcd for C<sub>19</sub>H<sub>17</sub>NNaO<sub>2</sub>S: 346.0878 found 346.0883. Anal. Calcd for C<sub>19</sub>H<sub>17</sub>NO<sub>2</sub>S: C, 70.78, H, 5.00, N, 4.34, S, 9.94. Found: C, 70.40, H, 5.25, N, 4.38, S, 9.69.

*N*-(5,6,7,8-tetrahydronaphthalen-1-yl)-1-naphthalenesulfonamide(14). Yield 45%, mp 187-189  $^{\circ}$ C, <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>)  $\delta$  = 1.34 (m, 2H), 1.47 (m, 2H), 2.34 (t, *J* = 6.2, 2H), 3.38 (t, *J* = 6.2, 2H), 6.70 (dd, *J* = 1.5, *J* = 7.54, 1H), 6.84 (d, *J* = 7.5, 1H),

6.87 (d, J = 7.5, 1H), 7.57 (t, J = 7.7, 1H), 7.65 (m, 2H), 8.05 (m, 2H), 8.20 (d, J = 8.29, 1H), 8.65 (m, 1H), 9.75 (bs, 1H, NH),<sup>13</sup>C NMR (75 MHz, DMSO-d<sub>6</sub>)  $\delta = 22.4$  (CH<sub>2</sub>), 22.5 (CH<sub>2</sub>), 24.6 (CH<sub>2</sub>), 29.3 (CH<sub>2</sub>), 123.7 (CH), 124.9 (CH), 125.1 (CH), 125.6 (CH), 127.2 (CH), 127.6 (CH), 127.9 (C), 128.0 (CH), 129.2 (CH), 129.3 (CH), 133.7 (C), 134.1 (C), 134.4 (CH), 134.8 (C), 136.4 (C), 138.3 (C), HRMS (ES<sup>+</sup>): m/z (M+H) calcd for C<sub>20</sub>H<sub>20</sub>NO<sub>2</sub>S: 338.1209 found: 338.1202.

#### 2.2. Biological Studies

#### 2.2.1. Cell culture

Jurkat (Acute T-cell Leukemia, a gift from Prof. Joan Gil, IDIBELL, Barcelona), Jeko-1 (Non-Hodgkin Lymphoma, a gift from Beatriz Martínez, CNIO, Madrid), JVM-2, Granta-549 (Non-Hodgkin Lymphoma, a gift from Dr. DolorsColomer, Hospital Clínic, Barcelona), and Z-138 (Non-Hodgkin Lymphoma, a gift from Dr. Eva Ortega-Paino, Lund University, Lund) were maintained in RPMI-1640 with L-Glutamine and HEPES (Biological Industries Ltd., Kibbutz BeitHaemek, Israel). LN229, U251, U373 (Glioma, a gift from Dr. Joan Seoane, Institut de RecercaValld'Hebron, Barcelona), SKMG-3 (Glioma, a gift from Dr.HansSkovgaard, Rigshospitalet, Oslo), PC-3 (Prostate Cancer, a gift from Prof. Anne J. Ridley, King's College, London), SW480 and SW620 (Colorectal cancer, a gift from Prof. Eric Lam, Imperial College, London) cells were maintained in DMEM High Glucose (4.5 g/l) with L-glutamine (Invitrogen, Carlsbad, CA). All cells were grown in a humidified incubator at 37°C with 5% CO<sub>2</sub>. RPMI and DMEM were supplemented with 10% heat inactivated foetal bovine serum and 100 units/ml penicillin/streptomycin (Sigma-Aldrich, St Louis, MO). All cell lines were subconfluently grown and passaged, routinely tested for mycoplasma contamination and subjected to frequent morphological tests and growth curve analysis as qualitycontrol assessments. All cell lines were treated at a prophylactic concentration of 5 µg/ml Plasmocin™ (InvivoGen, San Diego, CA).

#### 2.2.2. Cell Viability Analysis

The number of viable cells in culture was determined based on quantification of ATP, which signals the presence of metabolically-active cells, using the Cell Titer-Gloluminiscent assay kit (Promega, Madison, WI). Following the manufacturer's instructions, the cells were plated in 96-well plates, treated 24 h later with the compounds for the indicated times and concentrations, followed by addition of Cell

Titer-Glo reagent. Luminiscence was detected using a multi-well Synergy Mx scanning spectrophotometer (Biotek, Winooski, VT).

#### 2.2.3 Cell Cycle Analysis

Cell cycle analysis was performed using propidium iodide staining. Briefly, cells were washed in phosphate-buffered saline (PBS) and fixed in 70% ethanol(Sigma-Aldrich, St Louis, MO). Fixed cells were then washed twice in PBS and stained with50 µg/mlpropidium iodide (Sigma-Aldrich, St Louis, MO) in the presence of 50 µg/ml RNase A (Sigma-Aldrich, St Louis, MO), then analysed by flow cytometry using a FACScan (Coulter Epics XL-MSL, Beckman Coulter, Fullerton, CA) and winMDI software.

#### 2.2.4. Annexin V-FITC / propidium iodide flow cytometric analysis

Analysis of phosphatidylserine externalization in apoptotic cells was determined by an ApoTargetAnnexin-V-FITC Apoptosis kit (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions.  $2 \times 10^5$  cells were seeded in 6-well plates and treated as indicated. Cells were then collected and suspended in 100µl of Annexin V-binding buffer. 5µL of Annexin-V-FITC and 10µL of propidium iodide were added and incubated 15 min at room temperature in the dark. Flow cytometry analysis was carried out using a FACScan (Coulter Epics XL-MSL, Beckman Coulter, Fullerton, CA) and winMDI software.

#### 2.2.5. Caspase activity analysis

Enzymatic activity of caspases was determined by measurement of caspases-3 and 7 activity by means of the luminometricCaspase-Glo 3/7 assay (Promega, Madison, WI) according to the manufacturer's protocol using a Synergy HT multi-detection microplate reader (Bio-Tek, Winooski, VT).

#### 2.2.6. γ-H2A.X quantification

DNA damage was assessed monitoring the intensity of  $\gamma$  -H2A.X fluorescence using flow cytometry. Briefly, trypsinized cells were collected by centrifugation, washed in PBS and fixed in 3.7% formaldehyde(Sigma-Aldrich, St Louis, MO) for 15 min on ice. Cells were then permeabilized with 0.2% v/v Triton-X (Sigma-Aldrich, St Louis, MO)for 10 min, and incubated with 1:400 rabbit anti-p-(S139)-H2A.X antibody (Cell Signaling Technology, Beverly, MA) for 30 min on ice, washed in Triton-X 0.1% in PBS and incubated with 1:400 anti-rabbit Alexa 555-conjugated antibody (Jackson

ImmunoResearch, West Grove, PA) for 20 min on ice and washed. Flow cytometry analysis was carried out using a FACScan (Coulter Epics XL-MSL, Beckman Coulter, Fullerton, CA) and Flowing software.

#### 2.2.7. Clonogenic Assays

Cells were seeded in 12-well plates. 24 h later, cells were treated for 3h with 10  $\mu$ M **8e** or vehicle alone as a control. Cells were then washed with PBS, trypsinized and plated at low density (3000 cells/60-mm plate). Cells were allowed to divide and form colonies for 7–10 days. The colonies were fixed and stained with 0.5% (w/v) crystal violet(Sigma-Aldrich, St. Louis, MO) in 70% ethanol and the number of colonies counted. All experiments were performed in triplicate.

#### 2.2.8. Gel electrophoresis and immunoblotting

Cells were harvested in a buffer containing 50 mMTris-HCl pH 7.4, 150 mMNaCl, 1 mM EDTA and 1% (v/v) Triton X-100 plus protease and phosphatase inhibitors(all from Sigma-Aldrich, St. Louis, MO). Protein content was measured by the Bradford procedure. Cell lysates were electrophoresed in SDS-polyacrylamide gels. After electrophoresis the proteins were transferred to Immobilon-P strips (Millipore, Billerica, MA) for 2 h at 60 V. The sheets were pre-incubated in TBS (20 mMTris-HCl pH 7.5, 150 mMNaCl), 0.05% Tween 20 and 5% defatted milk powder for 1 h at room temperature and then incubated for 1 h at room temperature in TBS, 0.05% Tween 20, 1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) and 0.5% defatted milk powder containing the appropriate antibodies: p-Chk1 (Ref. 2348, Cell SignalingTechnology,Beverly, MA 1:1000) and  $\beta$ -tubulin (T0198, Sigma-Aldrich, St. Louis, MO, 1:4000). After washing in TBS, 0.05% Tween 20, the sheets were incubated with a peroxidase-coupled secondary antibody (Dako, Glostrup, Denmark, 1/2000 dilution,) for 1 h at room temperature. After incubation, the sheets were washed twice in TBS, 0.05% Tween 20 and once in TBS. The peroxidase reaction was visualized by the enhanced chemiluminiscence detection system (Millipore, Billerica, MA).

#### 2.2.9. Tubulin staining

Cells grown on coverslips were fixed in ice-cold Methanol (Sigma-Aldrich, St. Louis, MO)for 2 min, permeabilized in 0.2% (v/v) Triton X-100 for 30 min and blocked by incubating in 5% BSA for 30 min. Tubulin filaments were visualized by incubating the fixed cells for 1h at 37°C with anti- $\beta$ -Tubulin (T0198, Sigma-Aldrich, St. Louis, MO,

1:400), washing thrice in PBS and incubating with donkey anti-mouse-Alexa 488 (A21202, Life Technologies, Carlsbad, CA,1:400) in the presence of DAPI (32670, Sigma-Aldrich, St. Louis, MO, 1:300). Stained cells were analyzed on a Leica TCS SPE confocal microscope (Leica Microsystems, Wetzlar, Germany).

#### 2.2.10. Senescence Assays

Cells were plated subconfluently and treated for 24h with 10  $\mu$ M **8e**. Cells were then washed with PBS, fixed in 3% (v/v) formaldehyde in PBS for 10 min at room temperature, and then incubated with a stain solution containing 1 mg/ml of  $\beta$ -D-galactoside, for 24 h at 37 °C with the Senescence Cells Histochemical Staining Kit (CS0030, Sigma-Aldrich, St. Louis, MO). Blue-stained cells were counted in at least 10 fields at 10× magnification, and the number of stained cells was expressed as the percentage of positive cells relative to total cell number.

#### 2.2.11. Cell motility assays

MCF-7 cells and LN229 cells were plated in 6-well plates (4x10<sup>5</sup> cells/plate), wounded thrice with a sterile tip and 4 representative images were collected (time 0h). After 16 h, images of the same regions were collected and the ratio of cell motility in each experimental condition quantified.

#### 2.2.12 In vitro tubulin polymerization assays

The polymerization of purified monomeric tubulin *in vitro* was measured using the tubulin polymerization assay kit (Cytoskeleton Inc, Denver, CO) according to the manufacturer's instructions.Briefly, Tubulin (>99% pure) was reconstituted to 3 mg/ml in ice-cold 80 mM PIPES pH 6.9, 2 mM MgCl<sub>2</sub>, 0.5 mM EGTA, 1 mM GTP, 10.2% glycerol. 100  $\mu$ l of the reconstituted tubulin was added to each well of a 96-well plate (pre-warmed at 37 °C) and was either untreated or exposed to the indicated compounds at the specified concentrations, in duplicate. The absorbance at 340nm was measured every 60 sec for one hour at 37 °C using a Synergy HT multi-detection microplate reader (Bio-Tek, Winooski, VT).

#### 2.2.13 Statistical analysis

The statistical significance of differences was assessed by Student's *t* test using GraphPad Prism (GraphPad Software Inc. La Jolla, CA). Statistically significant differences are indicated by \*\*\*p<0.001, \*\*p<0.01 and \*p<0.05.

#### 2.3. DNA binding studies

Double-stranded ctDNA was purchased from commercial sources (Sigma-Aldrich, St. Louis, MO) and used without further purification. Polynucleotide was dissolved in sodium cacodylate buffer, I = 0.05 M (pH = 7.0), additionally sonicated and filtered through a 0.45 µm filter. DNA concentration per nucleotide was determined by absorption spectroscopy, using the molar extinction coefficient of 6600 M<sup>-1</sup>cm<sup>-1</sup> at 260 nm. The stock solution of compound **8e** was prepared, due the poor solubility in water, at a concentration of 1 mM in DMSO and diluted into buffer solution at the desired concentration.

#### 2.3.1. Thermal denaturation experiments

Thermal denaturation experiments were performed in a stoppered quartz cuvettes (1 cm path length) using an Agilent 8453 spectrometer equipped with a Peltier temperature controller system ( $\pm 0.1^{\circ}$  C). Thermal melting curves for ctDNA were determined by following the absorption change at 260 nm in the absence or presence of 8e as a function of temperature.

The absorbance intensity of wavelength 260 nm was measured over a temperature range 25-98°C. The temperature of the samples was raised in 0.5 °C increments and equilibrated for 1 min at each temperature setting. Absorbance of the ligands was subtracted from every curve, and the absorbance scale was normalized. The  $T_m$  values were taken as the midpoints of the transition curves, determined from the maximum of the first derivative and checked graphically by the tangent method.  $\Delta T_m$  values were calculated subtracting  $T_m$  for the free polynucleotide from  $T_m$  of the complex ctDNA-8e. Every  $\Delta T_m$  value here reported was the average of at least two measurements, the error in  $\Delta T_m$  is  $\pm 0.5$  °C.

#### 2.3.2. Fluorimetric experiments

Titration experiments were carried out at room temperature by adding increasing amounts of ctDNA to a  $1 \times 10^{-4}$  M ligand solution. All solutions were prepared in 50 mM sodium cacodylate buffer (pH 7.0) using doubly distilled water and passed through a Millipore apparatus. The absorbance of aqueous buffered solution of **8e** was proportional to their concentrations up to 100 µM. Hence, no significant intermolecular aggregation of the compounds, which would be expected to give rise to hypochromicity effects, occurred in the concentration range needed for the following spectroscopic studies. The emission spectra were recorded in the 317-500 nm range with excitation

wavelengths of 300 nm. Absorption and volume correction procedures were applied to the raw fluorescence data.

Ethidium Bromide Displacement Assays were recorded on a spectrofluorimeter in the 540–680 nm range with an excitation wavelength of 520 nm. The fluorescence was normalized by the maximum fluorescence signal when EB was bound to the DNA in the absence of competition for binding and was corrected for background fluorescence of free EB in solution.

#### 2.3.3. Circular dichroism experiments

CD spectra were recorded on a JASCO J815 spectropolarimeter between 400 and 200 nm in continuous scanning mode (50 nm/min, 1 nm bandwidth, and 1 s response time). All of the CD spectra were generated and represented averages of five scans. Measurements were performed by adding progressively increasing amounts of 8e to different solutions of ctDNA ( $1 \times 10^{-5}$  M) in 50 mMcacodylate buffer (pH 7).

#### 2.4. Docking experiments

The pdbs of tubulin in complex with benzenesulfonamides ABT-751 (3HKC.pdb) and T138067 (3HKE.pdb), colchicine (3UT5), pyrrolidinedione TN16 (3HKD), two enantiomericpyridopyrazines (3N2G.pdb and 3N2K.pdb) and podophyllotoxin (1SA1) were retrieved from the protein data bank [19] and only the chains and ligands corresponding to one tubulin dimer were used. The ligands were built with Spartan'08, prepared with AutodockTools[20] and docked with AutoDock 4.2[21] by running 100-300 times the Lamarckian genetic algorithm (LGA) with a maximum of 2.5 10<sup>6</sup> energy evaluations, 150 individuals in population and a maximum of 27000 generations. The results were analyzed with AutoDockTools and with an in-house developed java-based software tool [22].

#### 3. Results

Taking into account our previous results on antiparasitic agents targeting *L. infantum*  $\beta$ tubulin and the increasing therapeutic relevance of sulfonamide derivatives as antitumoral compounds, we decided to assess the potential anticancer activity of our sulfonamide library in a combined effort performing an array of cell biological and chemical studies in order to identify and characterize bioactive compounds. The insertion of the secondary sulfonamide group into the organic scaffolds is chemically straightforward and different methods have been adopted [23]. Sulfonamides **1-14** were prepared as previously described by condensation of the corresponding sulfonyl chloride with amine derivatives in pyridine at 0 °C [16]. The compounds were obtained in good yields and characterized by <sup>1</sup>H NMR and <sup>13</sup>C NMR spectroscopy, CHNS elemental analysis and HRMS.

#### 3.2. Biological activities

#### 3.2.1. Antiproliferative activities

All compounds were evaluated for their in vitroantiproliferative activity against a panel of representative human cancer cell lines, including cells from both solid tumors (colorectal, brain, prostate) and hematological malignancies (leukemia, lymphoma). Cells were treated for 48h with 10 µM of the indicated compounds and cell viability was assessed using a luminescent-based ATP assay. This commonly-used concentration was selected in our initial screen in order to discard as ineffective any compounds showing a negative biological effect. These results clearly indicated that one compound, sulfonamide 8e, showed a significant antiproliferative activity across the panel (Figure 2A). Similar results were obtained with additional cell lines including U87MG, U251, U373, Granta-519, JVM-2, Z-138, and SW480 (data not shown).In agreement with its effects on cell viability, phase-contrast microscopy indicated that treatment with 8e reduced LN229 and PC-3 cell proliferation and induced morphological changes consistent with the induction of cell death (Figure 2B). Doseresponse experiments in selected cell lines indicated that sulfonamide 8e was endowed with a pharmacologically-interesting antiproliferative activity in the nanomolar/low micromolar range, with IC<sub>50</sub> values ranging from 91 nM (Jurkat) to 17  $\mu$ M (PC-3) (Figure 2C). Differences in sensitivity are not likely to be related to expression of ATP-binding cassette drug transporters, since the IC<sub>50</sub> value for U87MG cells is within the same range as for LN229 cells (Figure 2C), and LN229 but not U87MG cells have been shown to overexpress P-gp and MRP-1 [24].

Based on the results obtained with **8e**, we decided to synthesize an additional series of compounds including naphthyl groups or related aromatic ringsin order to test whetherthis functional group could somehow be responsible for the antiproliferative

activity induced by **8e**. These compounds were tested for their antiproliferative activity against three representative cancer cell lines: Jeko-1, SKMG-3 and SW620, analyzing their viability at 48h upon a standard 10  $\mu$ M treatment. Surprisingly, none of the newly-synthesized compounds showed significant antiproliferative activity when compared to **8e** (Figure 2D). We thus proceeded to further characterize the cellular effects of **8e**, selected as the only active compound within this series of sulfonamides.

#### 3.2.2. Effect on Cell Cycle Progression and Cellular Senescence

Flow cytometry studies upon propidium iodide staining in a number of cell lines treated with 10  $\mu$ M **8e**were performed in order to analyze its impact on cell cycle progression. A 24h treatment with **8e** induced a remarkable increase in the G2/M population in both LN229 and PC-3 cells (Figure 3A), which led to a dramatic G2/M arrest at 48h in all the cell lines tested (Figure 3B). We next analyzed induction of cellular senescence upon **8e** treatment, performing a standard senescence assay based on the quantification of  $\beta$ -galactosidase positivity[25]. Whereas untreated PC-3 cells were  $\beta$ -gal negative at all observed time-points, treatment of PC-3 cells with **8e** led to a dramatic increase in the proportion of  $\beta$ -gal positive cells, already detectable at 24h and further increased at 48h and 72h (Figure 3C). These data indicate that prolonged cell cycle arrest induced by sulfonamide **8e** also leads to the induction of the cellular senescence program.

#### 3.2.3. Induction of apoptosis

We next assessed whether treatment with **8e** was also able to promote cellular death. For this purpose, we investigated whether treatment with **8e** could induce apoptosis in LN229 and PC-3 cells. Flow cytometric analysis upon double Annexin V /propidium iodide staining of **8e**-treated cells indicated that, in both cell lines, there was an increase in the early apoptotic (Annexin V-positive) fraction at 24h (Figure 4A). This was then followed by a dramatic shift of the cellular population to the early apoptotic quadrant at 72h, with a significant proportion of cells progressing to late apoptosis (double Annexin V and propidium iodide-positive cells, upper right quadrant) (Figures 4A and 4B).

In order to confirm that cell death in response to **8e** was associated with the activation of caspases, we analyzed caspase activation. For this purpose, we first assessed caspase 3 cleavage in response to **8e** treatment in LN229 and in the highly-sensitive

SKMG-3 cell line. As expected, exposure to **8e** led to the appearance of the low molecular bands indicative of cleaved, active caspase-3 (Figure 4C). In correlation with their higher sensitivity to **8e**, SKMG-3 cells showed a more dramatic induction of caspase-3 cleavage (Figure 4C). In agreement with these observations, treatment with 10  $\mu$ M **8e** for 48hinduced a detectable increase in the activity of the executioner caspases 3/7 in most cell lines (Figure 4D). Importantly, the levels of caspase activation inversely correlated with the reduction on cell viability induced by **8e** treatment in those same cell lines (Figure 4D). Taken together, these results indicate that prolonged treatment with **8e**, which rapidly induces a G2/M cell cycle arrest, leads to the onset of caspase-dependent apoptosis and thus to cell death.

#### 3.2.4. DNA damage analysis

In order to assess whether **8e** could induce cellular DNA damage we used flow cytometry to measure the staining of histone H2A.X phosphorylated at Ser-139 (also termed  $\gamma$ -H2AX) which is a well-established readout for DNA damage, since H2A.X becomes rapidly phosphorylated upon DNA double-strand breaks[26].Whereas only a modest background level of  $\gamma$ -H2AX staining was detected in untreated Z-138 cells, treatment with **8e** induced a clear shift yielding a  $\gamma$ -H2AX-positive population (Figure 5A). Quantification of  $\gamma$ -H2AX staining revealed a 6-fold increase upon **8e** treatment in Z-138 cells, and very similar results were also obtained in both LN229 and SP-53 cells (Figure 5B).

We next investigated whether **8e** could promote the sustained growth-inhibitory effects elicited by DNA-damaging agents, performing clonogenic assays upon a short exposure to **8e**. To this end, LN229 and PC-3 cells were treated with 10  $\mu$ M **8e** for 3h and seeded at low density to follow-up colony formation. Surprisingly, the clonogenicity of **8e**-treated cells was very similar to that of untreated cells (Figure 5C), whereas treatment with a standard genotoxic agent such as etoposide significantly reduced colony formation (data not shown).

In order to investigate whether **8e** was able to promote the activation of the DNA damage checkpoint, we analyzed the phosphorylation levels of the checkpoint signal-transducing kinase Chk1. As expected, treatment with etoposide clearly induced a time-dependent increase in the phosphorylation levels of Chk1. In sharp contrast, Chk1 activation was undetectable upon **8e** exposure as indicated by the absence of phosphorylation induction (Figure 5D). In agreement with these observations, studies

aimed at elucidating whether **8e** could structurally alter purified DNA *in vitro* yielded negative results. Thermal denaturation, fluorescence titration, ethidium bromide displacement assays and circular dichroism studies, all indicated low affinity binding, ruling out **8e** as an *in vitro* DNA-damaging compound (data not shown). Altogether, these observations indicate that **8e** does not induce cell cycle arrest secondary to the activation of the DNA damage checkpoint.

#### 3.2.5. Disruption of microtubuleassembly

Since the cellular effects of **8e** are compatible with the response to antimitotic agents, we next investigated whether 8e could alter the pattern of the microtubule network in a number of cell lines. In NIH3T3, T98G, LN229 and MCF-7 cells tubulin staining revealed a well-organized network of filamentous microtubules. In contrast, treatment with **8e** for 24h induced microtubule disassembly, with tubulin staining appearing as a disorganized meshwork mostly restricted to the perinuclear region (Figure 6A). Analysis of tubulin staining in synchronized, untreated, NIH3T3 cells indicated the presence of a well-formed mitotic spindle at ~24h shortly followed by cytokinesis. Importantly, neither the assembly of the mitotic spindle nor the presence of the cytokinetic ring was detected in 8e-treated cells (Figure 6B). Interestingly, in correlation with the effects of other established tubulin binders [27], long term treatment (>48h) with 8e also induced micronucleation (Figure 6C). We finally investigated whether 8e could directly influence tubulin polymerization in vitro. To this end, in vitro polymerization assays were performed to monitor the kinetics of tubulin polymerization in the absence or presence of 8e. Interestingly, 8e clearly induced a dose-dependent decrease in tubulin polymerization (Figure 6D). These results strongly indicate that sulfonamide 8e interferes with tubulin polymerization dynamics, leading to microtubule cytoskeleton malfunction and mitotic arrest.

#### 3.2.6. Inhibition of cancer cell motility

Since sulfonamide **8e** can interfere with tubulin polymerization, we investigated whether it could also inhibit cancer cell motility. To this end, we performed wound-healing assays using MCF-7 breast cancer cells and LN229 glioma cells, since they both are good models for cell motility assays. Both cell lines clearly showed a high rate of cell motility as indicated by the efficiency of gap closure at 16h. Interestingly, treatment with either 5  $\mu$ M or 10  $\mu$ M **8e** strongly reduced cell motility in both cell lines

(Figure 6E). These results indicate that **8e**, together with its previously described effects on cell proliferation, senescence and apoptosis, can inhibit cancer cell motility.

#### 3.2.7. Sulfonamide 8e is a reversible antimitotic agent

Since reversibility of antimitotic compounds is an important parameter in terms of predicting in vivo efficacy and undesirable side effects[28], we investigated the reversibility of the cellular effects of sulfonamide 8e. We first analyzed whether disrupting the treatment with 8e would lead to the proper re-assembly of the microtubule network. Interestingly, 48h after the removal of 8e, cells displayed a reorganized microtubule cytoskeleton (Figure 7A), which is completely undistinguishable from that of untreated cells (Figure 6A). In agreement with this, cell proliferation inhibition was also reverted 48h upon 8e washout, as indicated by the increase in both LN229 and PC-3 cell number detected in viability assays (Figure 7B). As expected, proliferation is accompanied byprogressive mitotic exit as indicated by the increase in the proportion of LN229 cells entering into the G1 phase of the cell cycle (Figure 7C). Remarkably, even the detection of senescence is reduced in a timedependent manner upon 8e removal in PC-3 cells (Figure 7D). Taken together, our observations clearly indicate that the cellular effects elicited by sulfonamide 8e are fully reversible.

#### 3.2.8. Docking studies and SAR analysis

With the goal of better understanding the structure–activity relationships, we performed docking experiments for the synthesized sulfonamides in different crystal structures of the colchicine site of tubulin in complex with structurally diverse ligands. From among these, the docking results for 3HKC, the complex of tubulin with the benzenesulfonamide ABT-751[29]were selected due to its higher structural similarity with the new compounds here described (Figure 8A). Overall the sulfonamides bind to the ABT-751 site with the two aromatic rings occupying the sites for the *p*-methoxyphenyl ring and the 2,3-diaminopyridine moiety of ABT-751, thus placing the sulphonamide brigde close to that of ABT-751, while the more deeply buried pocket for the *p*-aminophenol is only occupied by ligands with large ring systems, such as **9a-d**. The docked ligands show two different dispositions corresponding to the reversal of the sulfonamide moiety depending on the geometry of the attached aromatic rings, mainly to the benzofused ones. When there is only one *alpha* linked benzofused system (e.g. the naphthyl group in **8e**), it preferentially binds at the 2,3-diaminopyridine pocket, thus

allocating the other ring in the *p*-methoxyphenyl pocket. When two such *alpha* rings are present, both orientations can occur. When no *alpha* ring is present, the benzofusedsystems still prefer to bind at the 2,3-diaminopyridine pocket, as we can see for instance for **8b**. Therefore, the presence of the 1-naphthyl group causes a reversal in the binding mode for **8e**, which probably explains its different activity profile (Figure 8B). The same reversal is observed in**7a,b**but in these cases, it does not result in a potency increase. This is probably due to the lack of a substituent to replace the methoxy group of ABT-751 that is an important pharmacophoric element in the recognition of colchicine site ligands (hydrophobic site 1 of the pharmacophoric model of Nguyen et al. [30]) The introduction of additional nitrogen atoms is also detrimental for the activity, due to unsatisfied hydrogen bonds acceptor potential in the complexes.

#### 4. Discussion

In this report we have investigated the in vitro anticancer activities of our in-house panel of sulfonamides, consisting both of novel structures and previously-reported compounds some of which have shown interesting biological properties as antiparasitic agents [16]. The analysis of the antiproliferative activity of a series of 24 sulfonamidebased compounds in a comprehensive panel of representative human cancer cell lines indicated that only one compound, sulfonamide 8e, had clear antiproliferative properties. Since this compound was the only one within the series containing a naphthyl group, we reasoned that this structural motif might be responsible for its biological activity, and thus synthesized 12 additional sulfonamide compounds containing naphthyl or related aromatic rings such as guinolyl or dansyl moieties in order to test whether the naphthalene functional group was the major determinant of the activity of compound 8e. Surprisingly, however, none of the novel sulfonamides including naphthalene-related structures showed antiproliferative activity against three representative cancer cell lines, in contrast with the performance of 8e in these cells. The observation that only one compound within a series of highly-related structures promotes significant biological effects suggests that 8e is likely to specifically interfere with a cellular target.

Interestingly **8e** treatment led to a very robust cell cycle arrest and the induction of cellular senescence, which is a form of long-term and often irreversible proliferative arrest characterized by a larger and flattened cell shape and the expression of senescent markers such as  $\beta$ -galactosidase [31]. The observed G2/M arrest indicates

that sulfonamide **8e** impairs cell proliferation by preventing entry into mitosis or its completion. These results are compatible with the activation of the checkpoint pathway that imposes a G2 arrest in order to prevent mitosis entry following the detection of cellular DNA damage[32], which is normally observed in response to genotoxic agents. These results are also compatible with the detection of apoptotic cell death upon prolonged exposure to 8e. In agreement with this, a significant increase in  $\gamma$ -H2AX was detected in a number of cell lines treated with 8e, thus suggesting the presence of double-strand breaks in cellular DNA. An established assay to monitor the sustained antiproliferative effects of genotoxic agents is the analysis of cellularclonogenic capacity upon a transient exposure to such genotoxic drugs. Interestingly these assays indicated that, whereas a standard genotoxic agent such as etoposide induced a sustained antiproliferative effect, treatment with 8e was unable to reduce cellular clonogenicity, thus indicating that 8e does not promote the hallmark response of a DNA damage-inducing agent. In view of these conflicting observations, we directly monitored the activation of the DNA damage checkpoint by analyzing the phosphorylation levels of the checkpoint transducing kinase Chk1, which is rapidly phosphorylated in response to DNA damage and amplifies the checkpoint signal phosphorylating crucial downstream mediators [33]. The observation that the genotoxic agent etoposide, but not 8e, was able to induce an increase in Chk1 phosphorylation indicates that 8e does not promote the activation of the DNA damage checkpoint. In agreement with these observations, a number of studies including thermal denaturation, fluorescence titration, ethidium bromide displacement assays and circular dichroism measurements indicated low affinity binding of 8e with purified DNA. These observations suggest that8edoes not function as a genotoxic agent and therefore indicate that its cellular effects are likely to be unrelated to the observed increase in  $\gamma$ -H2AX. The most plausible explanation for the detection of  $\gamma$ -H2AX in the absence of other evidences of DNA damage, such as the observed lack of checkpoint activation, is the so called "pseudo DNA damage response" that has been reported in senescent cells. This response is characterized by the detection of  $\gamma$ -H2AX in senescent cells without the detection of DNA damage by direct measures of DNA fragmentation[34]. Taken together, our results indicate that despite the detection of  $\gamma$ -H2AX, presumably as a consequence of senescence induction, 8e does not function as a cellular genotoxic agent with the ability to induce the DNA damage checkpoint.

The observation that **8e** leads to a dramatic increase in G2/M content in the absence of a detectable measure of checkpoint activation, which would induce a G2 arrest,

strongly points to the disruption of mitotic progression as the key mechanism underlying the activity of 8e. The cellular effects of this compound are compatible with the hallmark response to other well-established anticancer agents inducing a G2/Mcontent increase followed by apoptosis: the mitotic poisons, such astubulin-binding agents. Due to the crucial role of microtubules for the completion of mitosis, tubulin heterodimers, the subunits of microtubules, constitute key cellular targets for the development of new anticancer drugs and thus tubulin inhibitors are currently used for the treatment of cancer. These inhibitors have antitumor activity by destabilizing tubulin polymerization, which alters microtubule dynamics and prevents the correct assembly of the mitotic spindle, leading to mitotic arrest. Several compounds, such as the taxanes, the vinca alkaloids, and estramustine all prevent cell cycle progression by inhibiting mitosis[35], and several tubulin binders are clinically-used chemotherapeutic agents[4]. Interestingly, a number of sulfonamides have been recently reported capable of binding microtubules and exerting antimitotic activity[7]. In agreement with our previous observations, 8e treatment led to a clear disruption of the microtubule cytoskeleton in a number of cell lines, with tubulin staining accumulating in the perinuclear region. Moreover, the formation of the mitotic spindle followed by the cytokinetic ring detected in synchronized NIH3T3 cells was not observed upon 8e treatment. Accordingly, in vitro tubulin polymerization assays with purified tubulin monomers confirmed that 8e is able to inhibit the polymerization of tubulin. Noteworthy, in correlation with our observations in response to 8e exposure, mitotic poisons such as paclitaxel[36], discodermolide[37], vincristine and vinblastine[38] also have been shown to induce cellular senescence and some of these compounds have also been reported to promote an increase in  $\gamma$ -H2AX[39]. Collectively, our data strongly indicate that sulfonamide 8e targets tubulin polymerization to elicit its cellular effects.

The dynamic regulation of the cellular cytoskeleton, including the microtubule network, is central to many complex cellular processes such as the control of cell shape and motility.Cell motility is frequently altered in cancer cells, which usually display a highly motile phenotype that is required to traverse the basal lamina and the endothelial layer of vessels in the process of localized invasion required for the metastatic dissemination of tumors [40]. Remarkably, and in agreement with its ability to disassemble the tubulin cytoskeleton, compound **8e** is also able to reduce cancer cell motility as indicated by our results in wound healing assays performed with MCF-7 and LN229 cells, thus improving its anticancer potential. Another interesting property displayed by some

antimitotic agents is reversibility of action, since compounds that disrupt microtubule dynamics show a wide degree of reversibility in their ability to block mitosis. The classic antimitotic compound colchicine, for instance, induces an almost irreversible mitotic block, whereas structurally-related colcemid exerts reversible effects. This property of mitotic poisons is not only compound-specific but also difficult to explain in terms of SAR: even small structural changes in compounds within a given class can lead to profound differences in mitotic block reversibility[41]. Reversibility is an important parameter in terms of predicting in vivo efficacy and undesirable side effects, as illustrated by the fact that slow dissociation from tubulin is thought to be the main reason behind colchicine's toxicity, which has led to its failure in the clinic[28]. Taking this into account, we investigated the cellular response upon **8e** removal. Interestingly, 8e washout led to a robust time-dependent reversion of its cellular effects, as shown by the full assembly of the tubulin cytoskeleton, the restoration of cell proliferation accompanied by progressive mitotic exit and concomitant G1 increase and, finally, the reduction of cellular senescence. This latter observation is remarkable since senescence has been, until recently,often described as an irreversible growth arrest. However, similar observations showing reversibility in the detection of senescent markers have also been previously reported, such as in ceramide-induced senescence[42] or in senescence induced by FGFR3 [43].

We finally show that docking studies and SAR analysis further confirm our experimental observations and strongly suggest that sulfonamide **8e** interacts with the colchicine site of tubulin. In summary, our data have enabled to identify a naphtalenesulfonamide, compound **8e**, as a potential anticancer agent with antiproliferative activity within a library of sulfonamide compounds. Exposure to **8e** leads to a dramatic G2/M arrest followed by the induction of apoptosis and the detection of cellular senescence, and also a reduction of cancer cell motility. These cellular effects, which are reversible upon removal of the compound, are likely related to the ability of **8e** to inhibit tubulin polymerization and thus mitotic progression, and therefore allow us to conclude that sulfonamide **8e** is a novel reversible antimitotic compound inhibiting cancer cell motility.

#### 5. Acknowledgements

This work was supported by the Spanish MINECO and FEDER (Consolider-Ingenio, Project CSD2010-000652010 and CTQ2013-48917-C3-1-P) and Generalitat

Valenciana (PROMETEO II 2015/002).C.G-R. thanks the Ministry of Education of Spain for a FPU Grant.We are grateful to Joan Seoane (Institut de Recerca Hospital Valld'Hebron, Barcelona), Hans Skovgaard (Rigshospitalet, Oslo), DolorsColomer (Hospital Clínic, Barcelona) and Beatriz Martínez (CNIO, Madrid) for cell lines, Manel Joaquin (Universitat Pompeu Fabra, Barcelona) for advice on  $\gamma$ -H2A.X staining and Antoni Costa (Universitat de les Illes Balears, Palma) for advice on non-linear regression analysis and IC<sub>50</sub> determinations. Rafael Peláez thanks Consejería de Educación, Junta de Castilla y León (SA147U13).

#### 6. Conflict of Interest Statement

The authors declare that there are no conflicts of interest.

#### 7. References

[1] American Cancer Society, Cancer Facts Fig. 2013 Rep. (2013). http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-factsfigures-2013 (accessed March 5, 2016).

[2] a) American Cancer Society, Treat. Types. (2016). http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes (accessed March 5, 2016).

b) World Health Organization, Cancer. (2015). http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed March 5, 2016).

c) C. Ceresa, A. Bravin, G. Cavaletti, M. Pellei, C. Santini, The Combined Therapeutical Effect of Metal-based Drugs and Radiation Therapy: The Present Status of Research, Curr. Med. Chem. 21 (2014) 2237–2265. doi:10.2174/0929867321666140216125721.

d) A. Rescifina, C. Zagni, M.G. Varrica, V. Pistarà, A. Corsaro, Recent advances in small organic molecules as DNA intercalating agents: Synthesis, activity, and modeling, Eur. J. Med. Chem. 74 (2014) 95–115. doi:10.1016/j.ejmech.2013.11.029.

e) A. Deepthi, S. Raju, A. Kalyani, M. UdayaKiran, A. Vanaja, Targeted Drug Delivery to the Nucleus and its Potential Role in Cancer Chemotherapy, J. Pharm. Sci. Res. 5 (2013) 48–56.

f) A. Mohan, S. Narayanan, S. Sethuraman, U.M. Krishnan, Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy, Anticancer Agents Med. Chem. 13 (2013) 281–95. doi:10.2174/1871520611313020015.

g) Z. Binkhathlan, A. Lavasanifar, P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives., Curr. Cancer Drug Targets. 13 (2013) 326–46. doi:10.2174/15680096113139990076.

h) I. Abraham, K. El Sayed, Z.S. Chen, H. Guo, Current status on marine products with reversal effect on cancer multidrug resistance, Mar. Drugs. 10 (2012) 2312–2321. doi:10.3390/md10102312.

i) M. Kollareddy, D. Zheleva, P. Dzubak, P.S. Brahmkshatriya, M. Lepsik, M. Hajduch, Aurora kinase inhibitors: Progress towards the clinic, Invest. New Drugs 30 (2012) 2411–2432. doi:10.1007/s10637-012-9798-6.

j) S.K. Singh, S.K. Tripathi, N. Dessalew, P. Singh, Cyclin Dependent Kinase as Significant Target for Cancer Treatment, Curr. Cancer Ther. Rev. 8 (2012) 225–235.

k) N. Gonen, Y.G. Assaraf, Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance, Drug Resist. Updat. 15 (2012) 183–210. doi:10.1016/j.drup.2012.07.002.

I) A. Urruticoechea, R. Alemany, J. Balart, A. Villanueva, F. Viñals, G. Capellá, Recent advances in cancer therapy: an overview, Curr. Pharm. Des. 16 (2010) 3–10. doi:10.2174/138161210789941847.

m) M. Nishiyama, H. Eguchi, Recent Advances in Cancer Chemotherapy: Current Strategies, Pharmacokinetics, and Pharmacogenomics, Adv. Drug Deliv. Rev. 61 (2009) 367–368. doi:10.1016/j.addr.2008.11.001.

[3] a) I. Marzo, J. Naval, Antimitotic drugs in cancer chemotherapy: Promises and pitfalls, Biochem. Pharmacol. 86 (2013) 703–710. doi:10.1016/j.bcp.2013.07.010.

b) K.W. Wood, W.D. Cornwell, J.R. Jackson, Past and future of the mitotic spindle as an oncology target, Curr. Opin. Pharmacol. 1 (2001) 370–377. doi:10.1016/S1471-4892(01)00064-9.

[4] a) E. Mukhtar, V.M. Adhami, H. Mukhtar, Targeting microtubules by natural agents for cancer therapy, Mol. Cancer Ther. 13 (2014) 275–84. doi:10.1158/1535-7163.MCT-13-0791.

b) D. Katsetos, Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside, Curr. Pharm. Des. 18 (2012) 2778–2792. doi:10.2174/138161212800626193.

c) Y. Lu, J. Chen, M. Xiao, W. Li, D.D. Miller, An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site, Pharm Res. 29 (2013) 2943–2971. doi:10.1007/s11095-012-0828-z.

d) C. Dumontet, M.A. Jordan, Microtubule-binding agents: a dynamic field of cancer therapeutics, Nat. Rev. Drug Discov. 9 (2010) 790–803. doi:10.1038/nrd3253.

a) P.K. Ranjith, R. Pakkath, K.R. Haridas, S.N. Kumari, Synthesis and [5] characterization N-(4-(4-chloro-1H-imidazol-1-yl)-3of new antimicrobial methoxyphenyl)amide/sulfonamide as possible derivatives and antitubercular J. Med. Chem. 71 (2014)354-365. agents, Eur. doi:10.1016/j.ejmech.2013.11.002.

b) T.A. Kirschberg, N.H. Squires, H. Yang, A.C. Corsa, Y. Tian, N. Tirunagari, et al., Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease, Bioorg. Med. Chem.Lett. 24 (2014) 969–972. doi:10.1016/j.bmcl.2013.12.060.

c) M.W. Carson, J.G. Luz, C. Suen, C. Montrose, R. Zink, X. Ruan, et al., Glucocorticoid receptor modulators informed by crystallography lead to a new rationale for receptor selectivity, function, and implications for structure-based design, J. Med. Chem. 57 (2014) 849–860. doi:10.1021/jm401616g.

d) S.S.A. Shah, G. Rivera, M. Ashfaq, Recent advances in medicinal chemistry of sulfonamides. Rational design as anti-tumoral, anti-bacterial and anti-inflammatory agents, Mini Rev. Med. Chem. 13 (2013) 70–86. doi:10.2174/138955713804484749.

e) A. Scozzafava, F. Carta, C.T. Supuran, Secondary and tertiary sulfonamides: a patent review (2008-2012), Expert Opin. Ther. Patents 23 (2013) 203–213. doi:10.1517/13543776.2013.742065.

f) G. Chen, H. Ren, A. Turpoff, A. Arefolov, R. Wilde, J. Takasugi, et al., Discovery of N-(4'-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication, Bioorganic Med. Chem. Lett. 23 (2013) 3942–3946. doi:10.1016/j.bmcl.2013.04.050.

g) T. Hanke, F. Rörsch, T.M. Thieme, N. Ferreiros, G. Schneider, G. Geisslinger, et al., Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1, Bioorg. Med. Chem. 21 (2013) 7874–7883. doi:10.1016/j.bmc.2013.10.006.

h) S. Ovais, S. Yaseen, R. Bashir, P. Rathore, M. Samim, S. Singh, et al., Synthesis and anti-inflammatory activity of celecoxib like compounds, J. Enzyme Inhib. Med. Chem. 28 (2012) 1105–1112. doi:10.3109/14756366.2012.710847.

i) I.R. Greig, E. Coste, S.H. Ralston, R.J. Van 'T Hof, Development of triarylsulfonamides as novel anti-inflammatory agents, Bioorganic Med. Chem. Lett. 23 (2013) 816–820. doi:10.1016/j.bmcl.2012.11.067.

j) A. Salahuddin, A. Inam, R.L. van Zyl, D.C. Heslop, C.-T. Chen, F. Avecilla, et al., Synthesis and evaluation of 7-chloro-4-(piperazin-1-yl)quinoline-sulfonamide as hybrid antiprotozoal agents, Bioorg. Med. Chem. 21 (2013) 3080–9. doi:10.1016/j.bmc.2013.03.052.

k) K.T. Andrews, G.M. Fisher, S.D.M. Sumanadasa, T. Skinner-Adams, J. Moeker, M. Lopez, et al., Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment, Bioorg. Med. Chem. Lett. 23 (2013) 6114–6117. doi:10.1016/j.bmcl.2013.09.015.

I) X. Chen, S. Hussain, S. Parveen, S. Zhang, Y. Yang, C. Zhu, Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications, Curr. Med. Chem. (2012) 3578–3604.

m) D. Patel, M. Jain, S.R. Shah, R. Bahekar, P. Jadav, A. Joharapurkar, et al., Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors, Bioorg. Med. Chem. Lett. 22 (2012) 1111–1117. doi:10.1016/j.bmcl.2011.11.122.

[6] L. Hu, Z. Li, J. Jiang, D.W. Boykin, Novel diaryl or heterocyclic sulfonamides as antimitotic agents., Anticancer Agents Med. Chem. 8 (2008) 739–745.

[7] a) S. Mehndiratta, Y.F. Chiang, M.J. Lai, H.Y. Lee, M.C. Chen, C.C. Kuo, et al., Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents, Bioorg. Med. Chem. 22 (2014) 4917–4923. doi:10.1016/j.bmc.2014.06.042.

b) A.P. Toner, F. McLaughlin, F.J. Giles, F.J. Sullivan, E. O'Connell, L. a Carleton, et al., The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance, Br. J. Cancer. 109 (2013) 2131–41. doi:10.1038/bjc.2013.537.

c) M.V.R. Reddy, M.R. Mallireddigari, V.R. Pallela, S.C. Cosenza, V.K. Billa, B. Akula, Design. synthesis. biological evaluation of (E)-N-aryl-2et al., and arylethenesulfonamide analogues as potent and orally bioavailable microtubuletargeted anticancer agents, Med. Chem. 56 (2013) 5562-86. J. doi:10.1021/jm400575x.

d) N. Abbassi, H. Chicha, E.M. Rakib, A. Hannioui, M. Alaoui, A. Hajjaji, et al., Synthesis, antiproliferative and apoptotic activities of N-(6(4)-indazolyl)benzenesulfonamide derivatives as potential anticancer agents, Eur. J. Med. Chem. 57 (2012) 240–249. doi:10.1016/j.ejmech.2012.09.013.

e) Y. Luo, K.M. Qiu, X. Lu, K. Liu, J. Fu, H.L. Zhu, Synthesis, biological evaluation, and molecular modeling of cinnamic acyl sulfonamide derivatives as novel antitubulin agents, Bioorg. Med. Chem. 19 (2011) 4730–4738. doi:10.1016/j.bmc.2011.06.088.

f) J. Chen, T. Liu, R. Wu, J. Lou, J. Cao, X. Dong, et al., Design, synthesis, and biological evaluation of novel *N*-γ-carbolinearylsulfonamides as anticancer agents, Bioorg. Med. Chem. 18 (2010) 8478–8484. doi:10.1016/j.bmc.2010.10.047.

g) Y.M. Wang, L.X. Hu, Z.M. Liu, X.F. You, S.H. Zhang, J.R. Qu, et al., N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer, Clin. Cancer Res. 14 (2008) 6218–6227. doi:10.1158/1078-0432.CCR-08-0550.

[8] a) S.M. Monti, C.T. Supuran, G. De Simone, Anticancer carbonic anhydrase inhibitors: a patent review (2008 - 2013), Expert Opin. Ther. Pat. 23 (2013) 737–49. doi:10.1517/13543776.2013.798648.

b) S.K. Suthar, S. Bansal, S. Lohan, V. Modak, A. Chaudhary, A. Tiwari, Design and synthesis of novel 4-(4-oxo-2-arylthiazolidin-3-yl) benzenesulfonamides as selective inhibitors of carbonic anhydrase IX over I and II with potential anticancer activity, Eur. J. Med. Chem. 66 (2013) 372–379. doi:10.1016/j.ejmech.2013.06.003.

c) J. Slawinski, K. Szafranski, D. Vullo, C.T. Supuran, Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, Eur. J. Med. Chem. 82 (2014) 47–55. doi:10.1016/j.ejmech.2014.05.039.

d) A. Husain, D. Madhesia, Heterocyclic compounds as carbonic anhydrase inhibitor., J. Enzyme Inhib. Med. Chem. 27 (2012) 773-783. doi:10.3109/14756366.2011.617882.

e) M.S. Al-Said, M.M. Ghorab, M.S. Al-Dosari, M.M. Hamed, Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety, Eur. J. Med. Chem. 46 (2011) 201–207. doi:10.1016/j.ejmech.2010.11.002.

[9] V. Turcotte, S. Fortin, F. Vevey, Y. Coulombe, J. Lacroix, M.-F. Côté, et al., Synthesis, Biological Evaluation and Structure-Activity Relationships of Novel Substituted *N*-Phenylureidobenzenesulfonate Derivatives Blocking Cell Cycle Progression in S-Phase and Inducing DNA Double-Strand Breaks., J. Med. Chem. 55 (2012) 6194-6208.doi:10.1021/jm3006492.

[10] a) A. Kamal, D. Dastagiri, M. JanakiRamaiah, J. Surendranadha Reddy, E. VijayaBharathi, M. Kashi Reddy, et al., Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents, Eur. J. Med. Chem. 46 (2011) 5817–5824. doi:10.1016/j.ejmech.2011.09.039.

b) F. Habens, N. Srinivasan, F. Oakley, D.A. Mann, A. Ganesan, G. Packham, Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity, Apoptosis. 10 (2005) 481–491. doi:10.1007/s10495-005-1877-0.

[11] a) J. Kim, P. Chun, H.R. Moon, Synthesis of Novel N-(2-Hydroxyphenyl)arylsulfonamides as Selective HDAC Inhibitory and Cytotoxic Agents, Bull. Korean Chem. Soc. 34 (2013) 1487–1493. doi:10.5012/bkcs.2013.34.5.1487.

b) E. Noaman, N. Fahmy, R. Yousri, O. El Shawi, M. Ghazy, Evaluation of the Antitumor and Radiosynthetizing Activity of a Novel Quinoline Sulfonamide Derivative (PIQSA) as a Histone Deacetylase Inhibitor, J. Cancer Ther. 2 (2011) 567–578. doi:10.4236/jct.2011.24077.

[12] P. Jain, C. Saravanan, S.K. Singh, Sulphonamides: Deserving class as MMP inhibitors?, Eur. J. Med. Chem. 60 (2013) 89–100. doi:10.1016/j.ejmech.2012.10.016.

[13] a) R. Schmieder, F. Puehler, R. Neuhaus, M. Kissel, A. a Adjei, J.N. Miner, et al., Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma, Neoplasia 15 (2013) 1161–1171. doi:10.1593/neo.13812.

b) Y. Luo, Y. Li, K.M. Qiu, X. Lu, J. Fu, H.L. Zhu, Metronidazole acid acyl sulfonamide: A novel class of anticancer agents and potential EGFR tyrosine kinase inhibitors, Bioorg. Med. Chem. 19 (2011) 6069–6076. doi:10.1016/j.bmc.2011.08.038.

c) N.S. Reddy, M.R. Mallireddigari, S. Cosenza, K. Gumireddy, S.C. Bell, E.P. Reddy, et al., Synthesis of new coumarin 3-(*N*-aryl) sulfonamides and their anticancer activity, Bioorg. Med. Chem. Lett. 14 (2004) 4093–4097. doi:10.1016/j.bmcl.2004.05.016.

[14] T. Haritunians, S. Gueller, J. O'Kelly, R. LLaria Jr., H. Phillip, Novel Acyl Sulfonamide LY573636-sodium: Effect on Hematopoietic Malignant Cells, Oncol Rep. 20 (2008) 1237–1242.

[15] a) J. Müller, A. Hemphill, New Approaches for the Identification of Drug Targets in Protozoan Parasites, in: Int. Rev. Cell Mol. Biol., Elsevier, 2013: pp. 359–401. doi:10.1016/B978-0-12-407704-1.00007-5.

b) R. Lama, R. Sandhu, B. Zhong, B. Li, B. Su, Identification of selective tubulin inhibitors as potential anti-trypanosomal agents, Bioorg. Med. Chem.Lett. 22 (2012) 5508–5516. doi:10.1016/j.bmcl.2012.07.023.

c) T.G. George, M.M. Endeshaw, R.E. Morgan, K. V. Mahasenan, D.A. Delfín, M.S. Mukherjee, et al., Synthesis, Biological Evaluation, and Molecular Modeling of 3,5-Substituted- $N^1$ -phenyl- $N^4$ ,  $N^4$  -di-n-butylsulfanilamides as AntikinetoplastidAntimicrotubule Agents, Bioorg. Med. Chem. 15 (2007) 6071–6079. doi:10.1016/j.bmc.2007.06.042.

[16] C. Galiana-Roselló, P. Bilbao-Ramos, M.A. Dea-Ayuela, M. Rolón, C. Vega, F. Bolás-Fernández, et al., In vitro and in vivo antileishmanial and trypanocidal studies of new *N*-benzene- and *N*-naphthalenesulfonamide derivatives, J. Med. Chem. 56 (2013) 8984–98. doi:10.1021/jm4006127.

[17] M.A.Dea-Ayuela, E. Castillo, M. Gonzalez-Alvarez, C. Vega, M. Rolón, F. Bolas-Fernández, et al., In vivo and in vitro anti-leishmanial activities of 4-nitro-*N*-pyrimidinand *N*-pyrazin-2-ylbenzenesulfonamides, and  $N^2$ -(4-nitrophenyl)- $N^1$ -propylglycinamide, Bioorg. Med. Chem. 17 (2009) 7449–7456. doi:10.1016/j.bmc.2009.09.030.

[18] J.F. Tilney-Basset, Introduction of a Sulphonamido-group by Means of Benzene- sulphonylAzide: An Unusual Substitution Pattern for Anthracene, J. Chem. Soc. (1962) 2517–2518.

[19] World Wide Protein Data Bank, (2016). http://www.wwpdb.org/ (accessed February 18, 2016).

[20] M.F.Sanner, Python: A Programming Language for Software Integration and Development, J. Mol. Graph. Mod. 17 (1999) 57–61.

[21] G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, et al., Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function, J. Comput. Chem. 19 (1998) 1639–1662. doi:10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B.

[22] R. García, C.A. Therón, R. López, J.L.Peláez, "JADOPPT: Java based AutoDock Preparing and Processing Tool" (unpublished work).

[23] S. Shoaib, A. Shah, T. Najjam, Synthetic Routes of Sulfonamide Derivatives: A Brief Review, Mini. Rev. Org. Chem. 10 (2013) 160–170. doi:10.2174/1570193X11310020005.

[24]O.Bähr, J.Rieger, F.Duffner, R.Meyermann, M.Weller, W.Wick,P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells, Brain Pathol.13(2003)482-494

[25] Itahana, K., Campisi, J., Dimri, G. P, Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidaseassay, Methods Mol. Biol. 371 (2007) 21-31.

[26] J. Lukas, C. Lukas, J. Bartek, More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance, Nat. Cell Biol. 13 (2011) 1161–1169. doi:10.1038/ncb2344.

[27]Y. Nakayama, N. Uno, K. Uno, Y. Mizoguchi, S. Komoto, Y. Kazuki, E. Nanba, T. Inoue, M. Oshimura, Recurrent micronucleation through cell cycle progression in the presence of microtubule inhibitors, Cell Struct. Funct. 40 (2015) 51-59.

[28] a) N.E. Thomas, R. Thamkachy, K.C. Sivakumar, K.J. Sreedevi, X.L. Louis, S. A Thomas, et al., Reversible action of diaminothiazoles in cancer cells is implicated by the induction of a fast conformational change of tubulin and suppression of microtubule dynamics, Mol. Cancer Ther. 13 (2014) 179–89. doi:10.1158/1535-7163.MCT-13-0479.

b) L. Sun, E. Hamel, C.M. Lin, S.B. Hastie, A. Pyluck, Kuo-Hsiung Lee, Antitumor Agents. 141. Synthesis and Biological Evaluation of Novel Thiocolchicine Analogs: *N*-Acyl-, *N*-Aroyl-, and *N*-( Substituted benzy)deacetylthiocolchicines as Potent Cytotoxic and Antimitotic Compounds, J. Med. Chem. 6 (1993) 1474–1479.

[29] A. Dorléans, B. Gigant, R.B.G. Ravelli, P. Mailliet, V. Mikol, M. Knossow, Variations in the colchicine-binding domain provide insight into the structural switch of tubulin, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 13775–13779. doi:10.1073/pnas.0904223106.

[30] T.L. Nguyen, C. McGrath, A.R. Hermone, J.C. Burnett, D.W. Zaharevitz, B.W. Day, et al., A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach, J. Med. Chem. 48 (2005) 6107–6116. doi:10.1021/jm050502t.

[31] D. Muñoz-Espín, M. Serrano, Cellular senescence: from physiology to pathology, Nat. Rev. Mol. Cell Biol. 15 (2014) 482–96. doi:10.1038/nrm3823.

[32] J. Bartek, J. Lukas, DNA damage checkpoints: from initiation to recovery or adaptation, Curr. Opin. Cell Biol. 19 (2007) 238–245. doi:10.1016/j.ceb.2007.02.009.

[33] J. Lukas, C. Lukas, J. Bartek, Mammalian cell cycle checkpoints: Signalling pathways and their organization in space and time, DNA Repair 3 (2004) 997–1007. doi:10.1016/j.dnarep.2004.03.006.

[34] T. V. Pospelova, Z.N. Demidenko, E.I. Bukreeva, V.A. Pospelov, A. V. Gudkov, M. V. Blagosklonny, Pseudo-DNA damage response in senescent cells, Cell Cycle. 8 (2009) 4112–4118. doi:10.4161/cc.8.24.10215.

[35] M. Schmidt, H. Bastians, Mitotic drug targets and the development of novel antimitotic anticancer drugs, Drug Resist. Updat. 10 (2007) 162–181. doi:10.1016/j.drup.2007.06.003.

[36] a) M. Prencipe, P. Fitzpatrick, S. Gorman, M. Tosetto, M. Mosetto, R. Klinger, et al., Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro, Br. J. Cancer. 101 (2009) 1900–8. doi:10.1038/sj.bjc.6605419.

b) J.Y.-F. Chen, C.-C. Hwang, W.-Y. Chen, J.-C. Lee, T.-F. Fu, K. Fang, et al., Additive effects of C(2)-ceramide on paclitaxel-induced premature senescence of human lung cancer cells, Life Sci. 87 (2010) 350–357. doi:10.1016/j.lfs.2010.06.017.

[37] L.E. Klein, B.S. Freeze, A.B. Smith, S.B. Horwitz, The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence, Cell Cycle 4 (2005) 501–507. doi:10.4161/cc.4.3.1550.

[38] a) L. Groth-Pedersen, M.S. Ostenfeld, M. Høyer-Hansen, J. Nylandsted, M. Jäättelä, Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine, Cancer Res. 67 (2007) 2217–2225. doi:10.1158/0008-5472.CAN-06-3520.

b) L. Duana, K. Sterba, S. Kolomeichuk, H. Kim, P.H. Brown, T.C. Chambers, Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest, Biochem.Pharmacol.73 (2007) 481–489.

[39] a) W.B. Dalton, M.O. Nandan, R.T. Moore, V.W. Yang, Human cancer cells commonly acquire DNA damage during mitotic arrest, Cancer Res. 67 (2007) 11487–11492. doi:10.1158/0008-5472.CAN-07-5162.

b) J.D. Orth, A. Loewer, G. Lahav, T.J. Mitchison, Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction, Mol. Biol. Cell. 23 (2012) 567–576. doi:10.1091/mbc.E11-09-0781.

[40] a) S. Etienne-Manneville, Microtubules in cell migration, Annu. Rev. Cell Dev. Biol. 29 (2013) 471–99.doi:10.1146/annurev-cellbio-101011-155711.

b) A. Wells, J. Grahovac, S. Wheeler, B. Ma, D. Lauffenburger, Targeting tumor cell motility as a strategy against invasion and metastasis, Trends Pharmacol. Sci. 34 (2013) 283–289. doi:10.1016/j.tips.2013.03.001.

[41] M.J. Towle, K.A. Salvato, B.F. Wels, K.K. Aalfs, W. Zheng, B.M. Seletsky, et al., Eribulin induces irreversible mitotic blockade: Implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions, Cancer Res. 71 (2011) 496–505. doi:10.1158/0008-5472.CAN-10-1874.

[42] R.E. Mouton, M.E. Venable, Ceramide induces expression of the senescence histochemical marker,  $\beta$ -galactosidase, in human fibroblasts, Mech. Ageing Dev. 113 (2000) 169–181. doi:10.1016/S0047-6374(99)00105-0.

[43] P. Krejci, J. Prochazkova, J. Smutny, K. Chlebova, P. Lin, A. Aklian, et al., FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence, Bone 47 (2010) 102–110. doi:10.1016/j.bone.2010.03.021.

#### 8. Figure Legends

Figure 1: Molecular structures of sulfonamides 1-14

Figure 2: Screening of sulfonamide compounds against human cancer cell lines.

(A) The indicated cell lines were treated for 48h with 10  $\mu$ M of the indicated sulfonamide compounds. The mean ±SD values from three independent experiments, each conducted in triplicate, are shown in the graph, representing the percentage of viable cells relative to untreated conditions. (B) Representative phase contrast micrographs of LN229 (top) and PC-3 (bottom) cells left untreated or treated for 24h and 48h with 10  $\mu$ M sulfonamide**8e.** (C) IC<sub>50</sub> mean values ±SD for the indicated cell lines, obtained from three independent experiments, each conducted in triplicate. (D) The indicated cell lines were treated for 48h with 10  $\mu$ M of the indicated sulfonamide compounds. The mean ±SD values from three independent experiments, each conducted in triplicate, are shown in the graph, representing the percentage of viable cells relative to untreated conditions.

Figure 3: Sulfonamide 8e induces G2/M arrest and cellular senescence.

(A) LN229 and PC-3 cells were left untreated or were treated for 24h and 48h with 10  $\mu$ M **8e**. Cells were harvested and their DNA content analyzed by flow cytometry as described in Methods. The cell cycle distribution is shown for each experimental condition. (B) The graph summarizes the flow cytometry data obtained in all tested cell lines, indicating the cell cycle distribution in control and **8e**-treated conditions (48h) for each cell line. (C) PC-3 cells were left untreated or treated for 48h with 10  $\mu$ M **8e** and stained for  $\beta$ -galactosidase as indicated in Methods. Themean ±SD values from three independent experiments, each conducted in triplicate, are shown in the graph, representing the percentage of  $\beta$ -galactosidase positive cells related to untreated conditions at the indicated time points.

Figure 4: Sulfonamide 8e induces apoptosis and activation of executioner caspases.

(A) LN229 and PC-3 cells were left untreated or were treated for 24h and 72h with 10 µM 8e. Cells were harvested, stained with Annexin V-FITC/Propidium lodide and analyzed by flow cytometry as described in Methods. The x-axis shows Annexin V-FITC staining and y-axis indicates Propidium iodide staining. The percentage of cells in each quadrant is shown. (B) The graph represents the fold increase in apoptotic LN229 and PC-3 cells, relative to untreated cells, at the indicated time-points. (C) LN229 and SKMG-3 cells were treated with10 µM 8e, harvested at the indicated time points and cellular extracts analyzed by inmunoblot with anti-caspase 3 antibodies.(D) The indicated cell lines were left untreated (control) or were treated for 48h with 10  $\mu$ M 8e and caspase 3/7 activity was measured as indicated in Methods. The data shows the mean ±SD values from three independentexperiments, each conducted in triplicate, representing the fold induction in caspase activity relative to untreated cells. (E)The indicated cell lines were left untreated (control) or were treated for 48h with 10 µM 8e and cell viability was measured as indicated in Methods. The data shows the mean ±SD values from three independent experiments, each conducted in triplicate, representing the percentage of viable cells relative to untreated cells.

(A) Z-138 cells were left untreated or were treated with for 4h with 10  $\mu$ M **8e**, harvested, stained with anti-pH2A.X and analyzed by flow cytometry as indicated in Methods. The histograms represent the fluorescent intensity (y-axis) of p-H2A.X-positive (x-axis) events. (B) The graphs summarizes the flow cytometry data obtained in all tested cell lines, representing the fold increase in p-H2A.X-positive fluorescence, relative to untreated cells (control). (C) LN229 and PC-3 cells were left untreated (control) or were treated for 3h with 10  $\mu$ M **8e** and plated at low density to measure their clonogenic potential as indicated in Methods. The graph represents the percentage of viable colonies, relative to control. (D) PC-3 cells were left untreated or were treated with 10  $\mu$ M **8e** or 30  $\mu$ M Etoposidefor the indicated time-points, harvested and cellular extracts analyzed by inmunoblot with the indicated specific antibodies. A representative inmunoblot (Top) and a graph indicating the mean quantified levels of p-Chk-1(Bottom) are shown.The differences between **8e** and etoposideare statistically significant (Student's *t*-test: \*\**P*<0.01).

Figure 6: Sulfonamide 8e disrupts the tubulin cytoskeleton and alters tubulin polymerization.

(A) The indicated cell lines were left untreated or were treated for 24h with 10  $\mu$ M 8e, fixed and stained with anti-Tubulin and DAPI as indicated in Methods. Bar, 20 μm.(B) NIH3T3 cells were arrested by serum deprivation for 48h, stimulated with 10% FCS to re-enter the cell cycle in the absence (untreated) or presence of 10 µM 8e, fixed at the indicated time-points and stained with anti-Tubulin and DAPI. Bar, 20 µm.(C) LN229 and SKMG-3 cells were left untreated or were treated for 48h with 10 µM 8e, fixed and stained with DAPI.Bar, 20 µm. (D)Purified tubulin was incubated in the presence of DMSO (control), paclitaxel, nocodazole or the indicated concentrations of 8e at 37º C. The graph depicts in vitro tubulin polymerization represented as the increase in absorbance at 340 nm (y-axis) over time (x-axis).(E)Representative phase-contrast micrographs of MCF-7 (left panel) and LN229 (right panel) cells left untreated or treated with 5 or 10  $\mu$ M 8e as indicated, before (upper panel, 0h) and after (lower panel, 16h) performing wound healing assays as described in Methods. The graph shows the mean  $\pm$ SD rate of motility, from three independent experiments performed in triplicate, expressed as the percentage of cell motility in each of the indicated conditions relative to untreated cells. The differences between control and **8e** treatment are statistically significant (Student's *t*-test: \*\**P*<0.01; \*\*\**P*<0.001).

#### Figure 7: Sulfonamide 8e is a reversible antimitotic.

(A) The indicated cell lines were treated for 24h with 10  $\mu$ M **8e**, washed to remove **8e**, fixed at the indicated time-points and stained with anti-Tubulin and DAPI as indicated in Methods.Bar, 20  $\mu$ m. (B) LN229 and PC-3 cells were treated for 24h with 10  $\mu$ M **8e**, washed to remove **8e**, and cell viability measured at the indicated time-points after

removal. The graph represents the fold increase in viable cells, relative to cells treated for 24h with **8e**. (C) LN229 cells were left untreated or treated for 24h with 10  $\mu$ M **8e**, washed to remove **8e**, harvested at the indicated time-points after removal and stained with propidium iodide and analyzed by flow cytometry. The cell cycle distribution is shown for each experimental condition. (D) PC-3 cells were left untreated or were treated for 24h with 10  $\mu$ M **8e**, washed to remove **8e** and stained for  $\beta$ -galactosidase at the indicated time-points after removal. The mean ±SD values from three independent experiments, each conducted in triplicate, are shown in the graph, representing the percentage of  $\beta$ -galactosidase positive cells related to untreated conditions at the indicated time points.

Figure 8: Docking studies support interaction of sulfonamide 8e with the colchicine site of tubulin.

(A) Structure of ABT-751 and generic structure of the sulfonamides. (B) Superposition of the docked dispositions of **8e** (carbons in maroon) and **8b** (carbons in olive) at the ABT-751 site, showing the reversal of the binding mode. The structure of ABT-751 (carbons in cyan) is shown for comparison.

COL

Figure 1





Figure 3 А 10 µM 8e Untreated 24h 48h G1: 52,8% S 19,3% G2M: 27,9% G1: 23,4% S 6,0% G2/M: 69,8% G1: 7,8% S: 5,3% G2/M: 86,9% 2 LN229 1 1 ۱ 10.00 10.00 61 23,7% S 10,2% G2/M 66,1% 61 .62,1% 61 10,1% S 9,8% G2/M 20\_1% S. 5,8% G2/M 84,1% PC-3 | ţ N.T.IR white: 10.4 В 100 90 80 70 = G2/M 60 5 50 #G1 40 30 20 10 0 10 µM 8e: + ÷ + ٠ ٠ . + Jeko-1 Jurkat NIH3T3 LN229 U87MG PC-3

RC

С









MCF-7

LN229



Figure 7



Time after 8e removal





